Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FQWC1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,284
Award facts
- Contract value 100% obligated
- $29,284.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,284.08 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. This delivery order, issued on November 18, 2025, with an ultimate completion date of November 19, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's recently established Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 contract awarded on November 13, 2025, that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations globally through December 31, 2036.
The PPV-G GEN V initiative represents part of the broader $30.3 billion Department of Defense pharmaceutical acquisition strategy designed to streamline medical supply chain operations across military healthcare facilities worldwide. Under this structure, the Defense Logistics Agency issues firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables. DMS Pharmaceutical Group's established track record supplying specialty pharmaceuticals, immunosuppressants, oncology treatments, vaccines, and other critical medications demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system with no identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DR26FQWC1?
SPE2DR26FQWC1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 18, 2025.
How much is contract SPE2DR26FQWC1 worth?
The government has obligated $29,284 on SPE2DR26FQWC1.
Is contract SPE2DR26FQWC1 an order under another contract?
Yes. SPE2DR26FQWC1 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWC1 competed?
The extent of competition for SPE2DR26FQWC1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award